News

Virginia Catalyst Announces Grant Round 15 Awarded Projects

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These four collaborative projects, involving Virginia research universities and industry partners, were awarded through Virginia Catalyst Grant Round 15 to address major unmet healthcare needs and drive job creation and capital formation in Virginia.

Through this 15th round of funding, Virginia Catalyst has awarded 61 grants totaling $29.7 million, resulting in over $47 million in matching funds and an additional $821 million in follow-on funding to date.

Grant Round 15 awarded projects:

Project: Transforming Asthma Treatment with a New Generation A2B Adenosine Receptor Antagonist

  • Company: Adovate, LLC  (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Tech
  • Funding amount: $800,000

Project: Optimization of a Wearable Enteral Feeding System for Commercialization

  • Company: Luminoah, Inc. (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Commonwealth University
  • Funding amount: $463,000

Project: Pre-clinical Evaluation of an Implant Device for the Regeneration of Severe Osteochondral Defects, Utilizing a Proven Novel Material and 3D Printing

  • Company: Nanochon, Inc. (Washington, DC)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $445,000

Project: Blocking the S1P Pathway for Chronic Kidney Disease Therapeutics

  • Company: S1P Therapeutics, Inc. (Blacksburg, VA)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $500,000

Recent News

02/17/2026

Serpin Pharma, Inc. Announces Approval to Initiate EASE‑AKI Phase II Clinical Trial in Germany

Serpin Pharma, Inc., a clinical‑stage biopharmaceutical company developing first‑in‑class LRP1‑agonist therapeutics, today announced that its Phase II clinical trial, EASE-AKI, has received unconditional approval to begin enrolling patients in Germany. The study will evaluate SP16, a powerful yet well-tolerated anti-inflammatory peptide, designed to protect the kidneys of patients with chronic kidney disease who are undergoing

02/09/2026

Activation Capital Expands Frontier BioHealth and Strengthens its Continuum of Support for Life Sciences Founders

Activation Capital today announced enhancements to Frontier BioHealth, building on the program’s successful 2024 launch and inaugural cohort while reinforcing its broader continuum of life sciences entrepreneurship programs designed to help science-driven companies progress toward commercialization and investor readiness. Frontier BioHealth was created to address a critical gap facing emerging biohealth founders: access to practical

02/04/2026

Governor Spanberger Announces Expansion of Paid Internship Opportunities with Virginia Businesses

Governor Abigail Spanberger today launched InternshipsVA, a new statewide program to help Virginia employers design and launch high-quality, paid internships for higher education students in Virginia. The Commonwealth has committed $14.5 million each year to support this program. The Governor was joined by leaders of the Virginia Chamber of Commerce, the Virginia Economic Development Partnership